Published in J Peripher Nerv Syst on June 01, 2011
Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol (2011) 1.38
Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol (2011) 1.25
Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurol (2012) 0.95
Immune pathogenesis and treatment of multifocal motor neuropathy. J Clin Immunol (2012) 0.89
Applying complement therapeutics to rare diseases. Clin Immunol (2015) 0.87
The pathogenesis of multifocal motor neuropathy and an update on current management options. Ther Adv Neurol Disord (2015) 0.77
Immunotherapy in Peripheral Neuropathies. Neurotherapeutics (2016) 0.76
Guillain-Barré syndrome: a century of progress. Nat Rev Neurol (2016) 0.76
MMN: from immunological cross-talk to conduction block. J Clin Immunol (2014) 0.76
Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study. J Neurol (2015) 0.76
The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights (2016) 0.75
Complement activity is associated with disease severity in multifocal motor neuropathy. Neurol Neuroimmunol Neuroinflamm (2015) 0.75
Terminal complement activation is increased and associated with disease severity in CIDP. Ann Clin Transl Neurol (2016) 0.75
Long-term Effects of Intravenous Cyclophosphamide in Combination with Mesna Provided Intravenously and via Bladder Perfusion in a Patient with Severe Multifocal Motor Neuropathy. Intern Med (2017) 0.75
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain (2008) 2.60
Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain (2010) 1.90
The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis. Nat Med (2010) 1.63
The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. J Hypertens (2004) 1.40
Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect Immun (2006) 1.34
Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. J Cell Biol (2006) 1.23
Modelling the incubation period of anthrax. Stat Med (2005) 1.22
Ganglioside antibodies and neuropathies. Curr Opin Neurol (2008) 1.15
Sialoadhesin promotes rapid proinflammatory and type I IFN responses to a sialylated pathogen, Campylobacter jejuni. J Immunol (2012) 1.14
Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Infect Immun (2002) 1.13
Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain (2004) 1.10
Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci (2009) 1.09
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve (2004) 1.09
Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiology (2009) 1.06
Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J Neurosci (2002) 1.05
Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol (2003) 1.04
Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci (2005) 1.02
Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J Physiol (2009) 1.01
Combinatorial glycoarray. Methods Mol Biol (2012) 1.01
The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest (2009) 1.00
Characterisation of the immunoglobulin variable region gene usage encoding the murine anti-ganglioside antibody repertoire. J Neuroimmunol (2005) 0.98
Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol (2005) 0.98
The Irish health system and the economic crisis. Lancet (2012) 0.97
Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav (2004) 0.95
Characteristics of residents and providers in the assisted living pilot program. Gerontologist (2007) 0.94
Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes. J Neuroimmunol (2004) 0.94
Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain (2003) 0.94
Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. Curr Opin Neurol (2002) 0.92
Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain (2003) 0.92
Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol (2005) 0.92
Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol (2011) 0.91
Adenovirus type 21-associated acute flaccid paralysis during an outbreak of hand-foot-and-mouth disease in Sarawak, Malaysia. Clin Infect Dis (2003) 0.90
Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol (2008) 0.89
Identity, developmental restriction and reactivity of extralaminar cells capping mammalian neuromuscular junctions. J Cell Sci (2008) 0.89
Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective. Neurochem Res (2002) 0.88
Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J Clin Invest (2012) 0.87
Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies. PLoS One (2012) 0.87
Challenges and implications of routine depression screening for depression in chronic disease and multimorbidity: a cross sectional study. PLoS One (2013) 0.86
Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. Glycobiology (2006) 0.86
Sialylation of Campylobacter jejuni lipo-oligosaccharides: impact on phagocytosis and cytokine production in mice. PLoS One (2012) 0.85
C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J Peripher Nerv Syst (2008) 0.85
Cognitive outcomes three years after coronary artery bypass surgery: a comparison of on-pump coronary artery bypass graft surgery and nonsurgical controls. Ann Thorac Surg (2005) 0.85
Self-reported memory symptoms with coronary artery disease: a prospective study of CABG patients and nonsurgical controls. Cogn Behav Neurol (2004) 0.85
The pre-synaptic motor nerve terminal as a site for antibody-mediated neurotoxicity in autoimmune neuropathies and synaptopathies. J Anat (2013) 0.84
Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions. Glia (2005) 0.84
Neuromuscular synaptic transmission in aged ganglioside-deficient mice. Neurobiol Aging (2009) 0.83
Antibodies to MOG in NMO: a seasoned veteran finds a new role. Neurology (2012) 0.83
Neuronal expression of GalNAc transferase is sufficient to prevent the age-related neurodegenerative phenotype of complex ganglioside-deficient mice. J Neurosci (2014) 0.82
A framework for assessing health system resilience in an economic crisis: Ireland as a test case. BMC Health Serv Res (2013) 0.81
Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome. Muscle Nerve (2002) 0.81
Motor nerve terminal destruction and regeneration following anti-ganglioside antibody and complement-mediated injury: an in and ex vivo imaging study in the mouse. Exp Neurol (2011) 0.80
Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barré syndrome. Org Biomol Chem (2004) 0.79
Ganglioside GM1 binding toxins and human neuropathy-associated IgM antibodies differentially promote neuritogenesis in a PC12 assay. Neurosci Res (2003) 0.78
Induction of human IgM and IgG anti-GM1 antibodies in transgenic mice in response to lipopolysaccharides from Campylobacter jejuni. J Neuroimmunol (2004) 0.78
A double-blind, clinical evaluation of facial augmentation treatments: a comparison of PRI 1, PRI 2, Zyplast and Perlane. J Plast Reconstr Aesthet Surg (2008) 0.78
Glycosphingolipid depletion in PC12 cells using iminosugars protects neuronal membranes from anti-ganglioside antibody mediated injury. J Neuroimmunol (2008) 0.78
Neurofascin antibodies in inflammatory neuropathy: how many needles make a haystack? Neurology (2012) 0.78
Total ganglioside ablation at mouse motor nerve terminals alters neurotransmitter release level. Synapse (2010) 0.78
In vitro analysis of glial cell function in ganglioside-deficient mice. J Neurosci Res (2009) 0.77
Autoantibodies in immune-mediated neuropathies. Curr Opin Neurol (2012) 0.77
Effect of perindopril on cerebral and renal perfusion on normotensives in mild early ischaemic stroke: a randomized controlled trial. Cerebrovasc Dis (2004) 0.77
Sulfatide binding properties of murine and human antiganglioside antibodies. Glycobiology (2007) 0.77
Concanavalin A inhibits pathophysiological effects of anti-ganglioside GQ1b antibodies at the mouse neuromuscular synapse. Muscle Nerve (2005) 0.76
Peripheral neuropathies: Establishing common clinical research standards for CIDP. Nat Rev Neurol (2011) 0.76
Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Curr Opin Neurol (2016) 0.76
The authors respond. Health Policy (2016) 0.75
Sugar refining reveals a further specificity for autoantibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry (2010) 0.75
A hazardous vapour trail from abattoir to neuropathy clinic. Lancet Neurol (2009) 0.75
Five-year follow-up of participants in a randomised controlled trial showing benefits from exercise for breast cancer survivors during adjuvant treatment. Are there lasting effects? J Cancer Surviv (2012) 0.75
The effects of age and ganglioside composition on the rate of motor nerve terminal regeneration following antibody-mediated injury in mice. Synapse (2013) 0.75
Peripheral neuropathies: Biomarkers for axonal damage in immune-mediated neuropathy. Nat Rev Neurol (2009) 0.75